Oltipraz

Oltipraz has an inhibitory effect on HIF-1α activation in a time-dependent manner, completely abrogating HIF-1α induction at ≥10 μM concentrations, the IC50 of Oltipraz for HIF-1α inhibition is 10 μM. Oltipraz is a potent Nrf2 activator.

Product Specifications

CAS Number

[64224-21-1]

Product Name Alternative

RP 35972; NSC 347901

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HIF/HIF Prolyl-Hydroxylase; HIV; Keap1-Nrf2; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Oltipraz.html

Concentration

10mM

Purity

99.87

Solubility

DMSO : 6 mg/mL (ultrasonic; warming)

Smiles

S=C1SSC(C2=NC=CN=C2)=C1C

Molecular Formula

C8H6N2S3

Molecular Weight

226.34

Precautions

H302, H315, H319, H335

References & Citations

[1]Lee WH, et al. Oltipraz and dithiolethione congeners inhibit hypoxia-inducible factor-1alpha activity through p70 ribosomal S6 kinase-1 inhibition and H2O2-scavenging effect. Mol Cancer Ther. 2009 Oct;8 (10) :2791-802.|[2]Ramos-Gomez M, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A. 2001 Mar 13;98 (6) :3410-5.|[3]Lv S, et al. Glucagon-induced extracellular cAMP regulates hepatic lipid metabolism. J Endocrinol. 2017 Aug;234 (2) :73-87.|[4]Eba S, et al.The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice.Am J Respir Cell Mol Biol. 2013 Aug;49 (2) :324-33.